Related Experiment Video
Updated: Dec 23, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Identification of prognostic factors for γδT cell immunotherapy in patients with solid tumor
Rishu Takimoto1, Tomoharu Miyashita2, Eishiro Mizukoshi3
1Seta Clinic Group, Tokyo, Japan; Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan.
Background Aims:
Activated γδT cells have been shown to exhibit cytotoxicity against tumor cells. However, the efficacy of γδT cell immunotherapy for a large number of patients with solid tumors remains unclear. In this study, we examined the efficacy of γδT cell immunotherapy using in vitro-activated γδT lymphocytes in combination with standard therapies in terms of the survival of patients with solid tumors, and determined prognostic factor for γδT cell immunotherapy.
Methods:
131 patients enrolled in this study received γδT cell immunotherapy with or without standard therapies. Their overall survival was analyzed by the Kaplan-Meier with log-rank test and Cox regression methods. Immunological analysis was performed by flow cytometry (FCM) before and after six cycles of γδT cell immunotherapy.
Results:
Multivariable analysis revealed that patients who showed stable disease (SD) and partial response (PR) to γδT cell immunotherapy showed better prognosis than those with a progressive disease (PD) (P = 0.0269, hazard ratio [HR], 0.410, 95% confidence interval [CI], 0.190-0.901). Furthermore, when immunological parameters were examined by FCM, the high Vγ9/γδT ratio (i.e., the high purity of the Vγ9 cells within the adoptively transferred γδT cells) before treatment was found to be a good prognostic factor for γδT cell immunotherapy (P = 0.0142, HR, 0.328, 95% CI, 0.125-0.801). No serious adverse events were reported during γδT cell immunotherapy.
Conclusion:
Thus, γδT cell immunotherapy might extend the survival of patients with solid tumors.
